Cassava Sciences, Inc. (SAVA) Stock Analysis
DELISTED
What happened to Cassava Sciences, Inc. (SAVA) stock?
Cassava Sciences, Inc. (SAVA) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $63.8M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Cassava Sciences, Inc. (SAVA). Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, particularly Alzheimer's disease. Their lead drug candidate is simufilam, a small molecule currently undergoing clinical trials.
Last analyzed: May 10, 2026These figures come from statements filed 13 months ago — the most recent this company has published.
Cassava Sciences, Inc. (SAVA) Healthcare & Pipeline Overview
More about this archive record
Can I still buy SAVA shares?
No. SAVA stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for SAVA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SAVA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Cassava Sciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.